Yuka Ishikawa

Dr. Yuka Ishikawa

Department of Pediatric Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Hokkaidō, Japan
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Neuromuscular Disorders
Verified
Journal Article
Closed access
Yuka IshikawaYuka Ishikawa
Yuka Ishikawa
TMToshihiko Miura
Toshihiko Miura
YIYukitoshi Ishikawa
Yukitoshi Ishikawa
TATomoyuki Aoyagi
Tomoyuki Aoyagi
HOHitoko Ogata
Hitoko Ogata
RMRyoji Minami
Ryoji Minami

1 January 1996 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Closed access
YIYukitoshi Ishikawa
Yukitoshi Ishikawa
Yuka IshikawaYuka Ishikawa
Yuka Ishikawa
RMRyoji Minami
Ryoji Minami
As dystrophin protein, the protein product of Duchenne muscular dystrophy (DMD) gene, represents only 0.002 approximately 0.03% of the total muscle proteins and human dystrophin protein has not been purified, quantitative estimation of this protein has been difficult. We describe a sensitive, reliable and convenient "two-antibody sandwich" enzyme-linked immunosorbent assay (ELISA) using commercially available monoclonal antibodies. This system, using a capture antibody specific for carboxyl terminus and two different detection antibodies for the mid-rod domain and the amino-terminal domain, is highly specific for dystrophin, since muscle specimens from DMD patients gave almost zero response (n = 3, 0.38 approximately 0.45%; expressed as a percentage of normal muscle tissue). This assay should prove to be an accessible and useful tool for the diagnosis of DMD/BMD and for the evaluation in clinical trials such as myoblast transfer and gene therapy.


1 July 2002
Verified
Journal Article
Closed access
KSKeisuke Sato
Keisuke Sato
Yuka IshikawaYuka Ishikawa
Yuka Ishikawa
YIYukitoshi Ishikawa
Yukitoshi Ishikawa
TITatsuro Izumi
Tatsuro Izumi
MOMinoru Okabe
Minoru Okabe
RMRyoji Minami
Ryoji Minami

1 October 2012 in American Journal of Physical Medicine & Rehabilitation
Verified
Journal Article
Closed access
SHSatoshi Hamada
Satoshi Hamada
Yuka IshikawaYuka Ishikawa
Yuka Ishikawa
TATomoyuki Aoyagi
Tomoyuki Aoyagi
YIYukitoshi Ishikawa
Yukitoshi Ishikawa
RMRyoji Minami
Ryoji Minami
JBJohn R. Bach
John R. Bach
There have been few reports of ventilator-induced lung injury associated with noninvasive ventilation (NIV), but many with invasive mechanical ventilation. The purpose of this study was to detect subclinical NIV-associated lung injury by monitoring Krebs von den Lungen glycoprotein plasma levels. Forty-one Duchenne muscular dystrophy patients were divided into three categories: group 1, asymptomatic and not using ventilators; group 2, NIV use less than 24 hrs/day at full ventilatory support settings; and group 3, continuous NIV dependence. Plasma Krebs von den Lungen glycoprotein level was measured by electrochemical luminescent immunoassay using Krebs von den Lungen glycoprotein antibodies. One-way analysis of variance, followed by the Tukey-Kramer test, was used as appropriate to compare intergroup differences. Extent of ventilator dependence correlated with age (P < 0.05). Intergroup plasma Krebs von den Lungen glycoprotein levels were not significantly different. NIV used at volumes and pressures of full (invasive) ventilatory support may not induce the alveolar septal barrier injury commonly seen with invasive mechanical ventilation.